WO2016016264A1 - Healthcare product made from magnesium for improving the functioning of living cells and associated device - Google Patents
Healthcare product made from magnesium for improving the functioning of living cells and associated device Download PDFInfo
- Publication number
- WO2016016264A1 WO2016016264A1 PCT/EP2015/067308 EP2015067308W WO2016016264A1 WO 2016016264 A1 WO2016016264 A1 WO 2016016264A1 EP 2015067308 W EP2015067308 W EP 2015067308W WO 2016016264 A1 WO2016016264 A1 WO 2016016264A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- care product
- magnesium
- magnesium chloride
- product according
- ingested
- Prior art date
Links
- 239000011777 magnesium Substances 0.000 title claims description 55
- 229910052749 magnesium Inorganic materials 0.000 title claims description 52
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 title claims description 51
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims abstract description 100
- 229910001629 magnesium chloride Inorganic materials 0.000 claims abstract description 52
- 230000000694 effects Effects 0.000 claims abstract description 41
- 230000001413 cellular effect Effects 0.000 claims abstract description 35
- 239000011785 micronutrient Substances 0.000 claims abstract description 28
- 235000013369 micronutrients Nutrition 0.000 claims abstract description 28
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract description 20
- 206010022000 influenza Diseases 0.000 claims abstract description 12
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 claims abstract description 7
- 201000004792 malaria Diseases 0.000 claims abstract description 7
- 208000005577 Gastroenteritis Diseases 0.000 claims abstract description 6
- 208000015122 neurodegenerative disease Diseases 0.000 claims abstract description 6
- 230000004770 neurodegeneration Effects 0.000 claims abstract description 5
- 208000037976 chronic inflammation Diseases 0.000 claims abstract description 4
- 208000037765 diseases and disorders Diseases 0.000 claims abstract description 4
- 210000004392 genitalia Anatomy 0.000 claims abstract description 4
- 230000006020 chronic inflammation Effects 0.000 claims abstract description 3
- 239000000047 product Substances 0.000 claims description 78
- 229960002337 magnesium chloride Drugs 0.000 claims description 51
- 229940091250 magnesium supplement Drugs 0.000 claims description 50
- 235000015872 dietary supplement Nutrition 0.000 claims description 40
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 23
- 239000011742 magnesium glycerophosphate Substances 0.000 claims description 21
- 235000001130 magnesium glycerophosphate Nutrition 0.000 claims description 21
- BHJKUVVFSKEBEX-UHFFFAOYSA-L magnesium;2,3-dihydroxypropyl phosphate Chemical compound [Mg+2].OCC(O)COP([O-])([O-])=O BHJKUVVFSKEBEX-UHFFFAOYSA-L 0.000 claims description 21
- 229910052739 hydrogen Inorganic materials 0.000 claims description 16
- 239000001257 hydrogen Substances 0.000 claims description 16
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 15
- 210000002700 urine Anatomy 0.000 claims description 15
- 208000001132 Osteoporosis Diseases 0.000 claims description 13
- 230000001143 conditioned effect Effects 0.000 claims description 10
- 206010020772 Hypertension Diseases 0.000 claims description 9
- 238000005259 measurement Methods 0.000 claims description 9
- 201000006417 multiple sclerosis Diseases 0.000 claims description 7
- 201000008482 osteoarthritis Diseases 0.000 claims description 7
- 208000024827 Alzheimer disease Diseases 0.000 claims description 6
- 235000009508 confectionery Nutrition 0.000 claims description 5
- 208000018737 Parkinson disease Diseases 0.000 claims description 4
- 229940050906 magnesium chloride hexahydrate Drugs 0.000 claims description 4
- DHRRIBDTHFBPNG-UHFFFAOYSA-L magnesium dichloride hexahydrate Chemical compound O.O.O.O.O.O.[Mg+2].[Cl-].[Cl-] DHRRIBDTHFBPNG-UHFFFAOYSA-L 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 239000002453 shampoo Substances 0.000 claims description 4
- 201000001320 Atherosclerosis Diseases 0.000 claims description 3
- 206010019280 Heart failures Diseases 0.000 claims description 3
- 238000005520 cutting process Methods 0.000 claims description 3
- 230000002526 effect on cardiovascular system Effects 0.000 claims description 3
- 150000004687 hexahydrates Chemical group 0.000 claims description 3
- 239000000344 soap Substances 0.000 claims description 3
- 230000005804 musculo-skeletal problem Effects 0.000 claims description 2
- 239000002884 skin cream Substances 0.000 claims description 2
- 239000000606 toothpaste Substances 0.000 claims description 2
- 229940034610 toothpaste Drugs 0.000 claims description 2
- 208000024172 Cardiovascular disease Diseases 0.000 abstract description 15
- 208000023178 Musculoskeletal disease Diseases 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 59
- 230000036541 health Effects 0.000 description 44
- 238000011282 treatment Methods 0.000 description 38
- 235000013305 food Nutrition 0.000 description 37
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 30
- 201000010099 disease Diseases 0.000 description 28
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical group [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 21
- 229910001425 magnesium ion Inorganic materials 0.000 description 21
- 238000000034 method Methods 0.000 description 20
- 230000002354 daily effect Effects 0.000 description 18
- 206010028980 Neoplasm Diseases 0.000 description 16
- 230000009471 action Effects 0.000 description 16
- 239000000499 gel Substances 0.000 description 16
- 230000007170 pathology Effects 0.000 description 15
- 241000894006 Bacteria Species 0.000 description 14
- 102000004190 Enzymes Human genes 0.000 description 13
- 108090000790 Enzymes Proteins 0.000 description 13
- 102000038379 digestive enzymes Human genes 0.000 description 13
- 108091007734 digestive enzymes Proteins 0.000 description 13
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 12
- 239000011575 calcium Substances 0.000 description 12
- 201000011510 cancer Diseases 0.000 description 12
- 210000000987 immune system Anatomy 0.000 description 12
- 230000002485 urinary effect Effects 0.000 description 12
- 230000003612 virological effect Effects 0.000 description 12
- 229910052791 calcium Inorganic materials 0.000 description 11
- 230000006870 function Effects 0.000 description 11
- 241000282414 Homo sapiens Species 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 10
- 239000008280 blood Substances 0.000 description 10
- 235000015097 nutrients Nutrition 0.000 description 10
- 230000007812 deficiency Effects 0.000 description 9
- 235000005911 diet Nutrition 0.000 description 9
- 230000037213 diet Effects 0.000 description 9
- 159000000003 magnesium salts Chemical class 0.000 description 9
- 208000024891 symptom Diseases 0.000 description 9
- 241000736262 Microbiota Species 0.000 description 8
- 238000005842 biochemical reaction Methods 0.000 description 8
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 8
- 230000000968 intestinal effect Effects 0.000 description 8
- 210000000936 intestine Anatomy 0.000 description 8
- 230000002265 prevention Effects 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 239000000796 flavoring agent Substances 0.000 description 7
- 239000008103 glucose Substances 0.000 description 7
- 206010020751 Hypersensitivity Diseases 0.000 description 6
- 208000008167 Magnesium Deficiency Diseases 0.000 description 6
- 230000007815 allergy Effects 0.000 description 6
- 230000001580 bacterial effect Effects 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 235000004764 magnesium deficiency Nutrition 0.000 description 6
- 230000000813 microbial effect Effects 0.000 description 6
- 230000008439 repair process Effects 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 6
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 5
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 5
- 241000282412 Homo Species 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 230000034994 death Effects 0.000 description 5
- 231100000517 death Toxicity 0.000 description 5
- 230000006735 deficit Effects 0.000 description 5
- 235000013355 food flavoring agent Nutrition 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 238000012423 maintenance Methods 0.000 description 5
- 210000003205 muscle Anatomy 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- 235000013311 vegetables Nutrition 0.000 description 5
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 4
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 4
- 102000004877 Insulin Human genes 0.000 description 4
- 108090001061 Insulin Proteins 0.000 description 4
- 208000000913 Kidney Calculi Diseases 0.000 description 4
- 206010029148 Nephrolithiasis Diseases 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 206010006451 bronchitis Diseases 0.000 description 4
- 230000008034 disappearance Effects 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 210000002216 heart Anatomy 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 229940125396 insulin Drugs 0.000 description 4
- 150000002500 ions Chemical class 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 235000021073 macronutrients Nutrition 0.000 description 4
- 210000000653 nervous system Anatomy 0.000 description 4
- 210000002569 neuron Anatomy 0.000 description 4
- 210000001672 ovary Anatomy 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 3
- 241000251468 Actinopterygii Species 0.000 description 3
- 201000009182 Chikungunya Diseases 0.000 description 3
- 208000005171 Dysmenorrhea Diseases 0.000 description 3
- 206010013935 Dysmenorrhoea Diseases 0.000 description 3
- 240000002129 Malva sylvestris Species 0.000 description 3
- 235000006770 Malva sylvestris Nutrition 0.000 description 3
- 201000005702 Pertussis Diseases 0.000 description 3
- 201000007100 Pharyngitis Diseases 0.000 description 3
- 206010039792 Seborrhoea Diseases 0.000 description 3
- 229910052782 aluminium Inorganic materials 0.000 description 3
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 3
- 229910052785 arsenic Inorganic materials 0.000 description 3
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 238000004061 bleaching Methods 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 235000013351 cheese Nutrition 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 210000002249 digestive system Anatomy 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 230000036449 good health Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 201000010260 leiomyoma Diseases 0.000 description 3
- 235000013372 meat Nutrition 0.000 description 3
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 3
- 229910052753 mercury Inorganic materials 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 238000009928 pasteurization Methods 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 208000020016 psychiatric disease Diseases 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 206010044008 tonsillitis Diseases 0.000 description 3
- 238000002604 ultrasonography Methods 0.000 description 3
- 210000004291 uterus Anatomy 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 206010001497 Agitation Diseases 0.000 description 2
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 201000006082 Chickenpox Diseases 0.000 description 2
- 206010011732 Cyst Diseases 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 201000005505 Measles Diseases 0.000 description 2
- 208000005647 Mumps Diseases 0.000 description 2
- 208000007101 Muscle Cramp Diseases 0.000 description 2
- 206010029216 Nervousness Diseases 0.000 description 2
- 208000005141 Otitis Diseases 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 208000000450 Pelvic Pain Diseases 0.000 description 2
- 208000000474 Poliomyelitis Diseases 0.000 description 2
- 206010039587 Scarlet Fever Diseases 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 206010043376 Tetanus Diseases 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 206010046980 Varicella Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 206010003549 asthenia Diseases 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000033077 cellular process Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 208000031513 cyst Diseases 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000002498 deadly effect Effects 0.000 description 2
- 230000001079 digestive effect Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 235000011869 dried fruits Nutrition 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 208000019258 ear infection Diseases 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000000105 enteric nervous system Anatomy 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 238000004880 explosion Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 235000012631 food intake Nutrition 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 208000014617 hemorrhoid Diseases 0.000 description 2
- 239000000017 hydrogel Substances 0.000 description 2
- -1 hydrogen ions Chemical class 0.000 description 2
- GPRLSGONYQIRFK-UHFFFAOYSA-N hydron Chemical compound [H+] GPRLSGONYQIRFK-UHFFFAOYSA-N 0.000 description 2
- 230000001631 hypertensive effect Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000009776 industrial production Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 2
- 239000001095 magnesium carbonate Substances 0.000 description 2
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 235000020802 micronutrient deficiency Nutrition 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 230000008450 motivation Effects 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 208000010805 mumps infectious disease Diseases 0.000 description 2
- 230000037312 oily skin Effects 0.000 description 2
- 238000001139 pH measurement Methods 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 208000017497 prostate disease Diseases 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 201000005404 rubella Diseases 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 201000009890 sinusitis Diseases 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 235000014347 soups Nutrition 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 235000019168 vitamin K Nutrition 0.000 description 2
- 239000011712 vitamin K Substances 0.000 description 2
- 239000002699 waste material Substances 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- 235000013618 yogurt Nutrition 0.000 description 2
- UPLPHRJJTCUQAY-WIRWPRASSA-N 2,3-thioepoxy madol Chemical compound C([C@@H]1CC2)[C@@H]3S[C@@H]3C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@](C)(O)[C@@]2(C)CC1 UPLPHRJJTCUQAY-WIRWPRASSA-N 0.000 description 1
- YPFNIPKMNMDDDB-UHFFFAOYSA-K 2-[2-[bis(carboxylatomethyl)amino]ethyl-(2-hydroxyethyl)amino]acetate;iron(3+) Chemical compound [Fe+3].OCCN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O YPFNIPKMNMDDDB-UHFFFAOYSA-K 0.000 description 1
- AUNGANRZJHBGPY-MBNYWOFBSA-N 7,8-dimethyl-10-[(2R,3R,4S)-2,3,4,5-tetrahydroxypentyl]benzo[g]pteridine-2,4-dione Chemical compound OC[C@H](O)[C@H](O)[C@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-MBNYWOFBSA-N 0.000 description 1
- 206010000242 Abortion threatened Diseases 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 208000000412 Avitaminosis Diseases 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- 208000010392 Bone Fractures Diseases 0.000 description 1
- 206010006326 Breath odour Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- 208000004434 Calcinosis Diseases 0.000 description 1
- 241001244373 Carex spissa Species 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 206010017076 Fracture Diseases 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000031220 Hemophilia Diseases 0.000 description 1
- 208000009292 Hemophilia A Diseases 0.000 description 1
- 208000037221 Hepatic congestion Diseases 0.000 description 1
- 206010020100 Hip fracture Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000002979 Influenza in Birds Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 1
- 206010028347 Muscle twitching Diseases 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 208000001164 Osteoporotic Fractures Diseases 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010037294 Puerperal pyrexia Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000036071 Rhinorrhea Diseases 0.000 description 1
- 206010039101 Rhinorrhoea Diseases 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 208000005985 Threatened Abortion Diseases 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 206010047141 Vasodilatation Diseases 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- 206010047627 Vitamin deficiencies Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000002804 anti-anaphylactic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002180 anti-stress Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 208000037849 arterial hypertension Diseases 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 206010064097 avian influenza Diseases 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 235000013405 beer Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 238000010876 biochemical test Methods 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 208000027499 body ache Diseases 0.000 description 1
- 235000015496 breakfast cereal Nutrition 0.000 description 1
- 239000011449 brick Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 235000013574 canned fruits Nutrition 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 201000011529 cardiovascular cancer Diseases 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000004635 cellular health Effects 0.000 description 1
- 230000004098 cellular respiration Effects 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 150000003841 chloride salts Chemical class 0.000 description 1
- 201000001352 cholecystitis Diseases 0.000 description 1
- 201000001883 cholelithiasis Diseases 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 235000019987 cider Nutrition 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 208000006111 contracture Diseases 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 201000003146 cystitis Diseases 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 239000000551 dentifrice Substances 0.000 description 1
- 239000002781 deodorant agent Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 230000002542 deteriorative effect Effects 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 235000015177 dried meat Nutrition 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000018927 edible plant Nutrition 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 235000019688 fish Nutrition 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000021022 fresh fruits Nutrition 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 239000000446 fuel Substances 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 208000024386 fungal infectious disease Diseases 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 208000001130 gallstones Diseases 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000002641 glycemic effect Effects 0.000 description 1
- 244000005709 gut microbiome Species 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000008821 health effect Effects 0.000 description 1
- 210000002064 heart cell Anatomy 0.000 description 1
- 230000003284 homeostatic effect Effects 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 210000002758 humerus Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 230000009474 immediate action Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000007124 immune defense Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 229960001438 immunostimulant agent Drugs 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000002917 insecticide Substances 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 208000028774 intestinal disease Diseases 0.000 description 1
- 230000035987 intoxication Effects 0.000 description 1
- 231100000566 intoxication Toxicity 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 230000002475 laxative effect Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 235000020793 low-cost food Nutrition 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000003050 macronutrient Effects 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000007257 malfunction Effects 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 208000004396 mastitis Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000004630 mental health Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229910052750 molybdenum Inorganic materials 0.000 description 1
- 239000011733 molybdenum Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 230000004220 muscle function Effects 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 230000008035 nerve activity Effects 0.000 description 1
- 230000002232 neuromuscular Effects 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 235000013348 organic food Nutrition 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- PGZUMBJQJWIWGJ-ONAKXNSWSA-N oseltamivir phosphate Chemical compound OP(O)(O)=O.CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 PGZUMBJQJWIWGJ-ONAKXNSWSA-N 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-O oxonium Chemical compound [OH3+] XLYOFNOQVPJJNP-UHFFFAOYSA-O 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 208000035824 paresthesia Diseases 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 230000005195 poor health Effects 0.000 description 1
- 235000020004 porter Nutrition 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229910001414 potassium ion Inorganic materials 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- SBYHFKPVCBCYGV-UHFFFAOYSA-N quinuclidine Chemical compound C1CC2CCN1CC2 SBYHFKPVCBCYGV-UHFFFAOYSA-N 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 210000002320 radius Anatomy 0.000 description 1
- 235000020185 raw untreated milk Nutrition 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 229940061374 relenza Drugs 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 230000036186 satiety Effects 0.000 description 1
- 235000019627 satiety Nutrition 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000001932 seasonal effect Effects 0.000 description 1
- 208000008742 seborrheic dermatitis Diseases 0.000 description 1
- 210000002374 sebum Anatomy 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 229940061367 tamiflu Drugs 0.000 description 1
- 235000015113 tomato pastes and purées Nutrition 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 210000000623 ulna Anatomy 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
- ARAIBEBZBOPLMB-UFGQHTETSA-N zanamivir Chemical compound CC(=O)N[C@@H]1[C@@H](N=C(N)N)C=C(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO ARAIBEBZBOPLMB-UFGQHTETSA-N 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the present invention relates to a care product, including a food supplement, for improving the functioning of living cells and a device associated with this care product. It applies to the areas of well-being and the prevention of cellular dysfunctions.
- Cardio-vascular diseases are all disorders of the heart and blood circulation. At the global level, WHO estimates that these diseases affect 2.1 billion people or about 30% of the population. They are responsible for 30% of deaths worldwide, and are the leading cause of disability. Among these diseases, high blood pressure will affect in 2025, 29.2% of the world population, more than 2 billion people. Remember that high blood pressure is just one of the many cardiovascular diseases listed. These few figures demonstrate that cardiovascular disease is now a major global problem.
- pandemics we mentioned above are therefore very worrying, but others also break lives irreparably. These are Alzheimer's disease, Parkinson's disease, multiple sclerosis, and osteoarthritis.
- the present invention aims to remedy all or part of these disadvantages.
- the present invention aims a care product to reduce the risk of occurrence of at least one of the following diseases and disorders, by improving the cellular biochemical activity:
- the inventor has, in fact, discovered and demonstrated that the use of magnesium helped prevent all or part of these diseases and disorders.
- the care product of the present invention takes the form of a dietary supplement.
- the care product of the present invention comprises at least 90% magnesium chloride in hexahydrate form (MgCl 2 .6H 2 O).
- the care product of the present invention is conditioned for a daily intake of magnesium chloride hexahydrate greater than or equal to 1 gram, and preferably 2.5 grams.
- the care product of the present invention takes the form of liquid, crystals or powder.
- the powder is extracted from a mine, without the addition of cutting product.
- This type of dietary supplement has an absence of arsenic, lead, mercury, aluminum and has a limited cost.
- the care product which is the subject of the present invention is conditioned for a magnesium journaling intake greater than or equal to 120 mg, and preferably 300 mg.
- the care product of the present invention is conditioned for several doses of magnesium chloride, each day.
- the care product of the present invention is conditioned to prevent the effects of influenza, for:
- the care product of the present invention comprises a mixture:
- magnesium glycerophosphate magnesium glycerophosphate
- the amount, by mass, of magnesium glycerophosphate is greater than the amount, by mass, of magnesium chloride.
- the amount, by mass, of magnesium glycerophosphate is greater than five times the amount, by mass, of magnesium chloride.
- the proportion by weight of magnesium chloride, magnesium glycerophosphate and water is greater than 95%.
- the care product of the present invention takes the form of a gel.
- the present invention relates to a care product which comprises a mixture:
- magnesium glycerophosphate The inventor has discovered that this mixture can take, depending on the proportions of the two constituents and its drying, the form of a gel, a paste or a solid which can be introduced into many products.
- the amount, by mass, of magnesium glycerophosphate is greater than the amount, by mass, of magnesium chloride.
- the amount, by mass, of magnesium glycerophosphate is greater than five times the amount, by mass, of magnesium chloride.
- the proportion by weight of magnesium chloride, magnesium glycerophosphate and water is greater than 95%.
- the inventor has determined that these proportions promote the formation of a gel.
- a gel is a solid which can have properties ranging from soft and ductile to hard and brittle.
- Gels are defined as highly diluted entangled systems with no flow when in a stable state. In bulk, the gels are mainly made of liquid. Yet they behave like solids thanks to their three-dimensional network entangled within the liquid. It is these entanglements that give the gels their structure (hardness) and contribute to their adhesion.
- a gel is a three-dimensional network of solids diluted in a fluid. This network may be the result of chemical or physical bonds, or small crystals or other bonds that remain intact in the carrier fluid.
- any fluid can serve as a carrier, including water (hydrogel), oil or air (airgel).
- the gels are mainly composed of the fluid, and therefore have densities close to those of the latter.
- Gelatin is a common example of a hydrogel and has a density close to that of water.
- the care product of the present invention comprises a flavoring agent.
- the flavoring agent imparts a sweet flavor to the dietary supplement.
- the care product of the present invention takes the form of a gel.
- the present invention relates to a shampoo, comprising a care product object of the present invention.
- the present invention relates to a soap comprising a care product object of the present invention.
- the present invention provides a cream comprising a care product object of the present invention.
- the present invention is directed to a dentifrice comprising a care product which is the subject of the present invention.
- the present invention aims a candy comprising a care product object of the present invention.
- the present invention is directed to a device for measuring the hydrogen potential pH of urine to determine an amount to be ingested of a care product according to the present invention, which comprises a means for comparing the hydrogen potential with a table of quantities of said care product to be ingested according to the measured pH hydrogen potential.
- the table of quantities of said care product to be ingested indicates a quantity of care product to be ingested daily.
- the table of quantities of said care product to be ingested indicates an increase in the amount of said care product to be ingested, for a measurement of the hydrogen potential pH of the urine greater than 6.2, relative to a corresponding amount. to a measurement of the hydrogen potential pH less than 6.2.
- the table of quantities of said care product to be ingested indicates an increase in the amount of said care product to be ingested, for a measurement of the hydrogen potential pH of the urine greater than 6.2, relative to a corresponding amount. to a measurement of the hydrogen potential pH between 5.0 and 6.2.
- Health is therefore a long-term survival process, created by the cells more than 3.5 billion years ago.
- any multicellular being - of which we are - is an assembly of autonomous cells, which function in a coordinated way by exchanging information, thus constituting a network.
- cellular know-how has improved and become increasingly complex over time, cellular health expertise is unique and without comparison with our current human knowledge.
- Each human being is composed of 10,000 billion connected cells, experts in health, whose sole purpose is to maintain the permanence of health.
- Health is a cellular competence, characterized by the capacity of each cell of an organism, in real time and in coordination with the other cells, to ensure the totality of the biochemical reactions of which she is in charge.
- the cells must have an indispensable material in sufficient quantity: the micronutrients. Health maintenance is only possible under this condition. Nutrients are the molecules that can be used directly by cells without any chemical modification, the role of our digestive system being to extract nutrients from our diet in order to make them available to our cells.
- Micronutrients include amino acids, fatty acids, glucose, fructose, galactose and water. They structure our body and supply it with energy.
- Micronutrients are vitamins A, B, C, D, E and K, minerals such as calcium, magnesium, phosphorus, potassium, and sodium, and trace elements such as chromium, copper, iron , fluorine, iodine, manganese, molybdenum, selenium and zinc ...
- Micronutrients are essential for the enzymes that are responsible for cellular biochemical activity. Without micronutrient, no cellular biochemical activity, and therefore no life. However, our diet is too rich in macronutrients and too poor in micronutrients. The conditions are not there for our cells to function properly.
- micronutrients among the micronutrients, one of them is particularly interesting. He alone is involved in more than three hundred essential biochemical reactions. A micronutrient that, if available in sufficient quantities in our diet, would provide effective prevention of cardiovascular disease, diabetes, osteoporosis and nervous breakdown, in short, a set of pandemics current. This micronutrient is magnesium.
- Live foods are foods that contain cells and have not been refined, processed, heated to over 45 ° C or ionized. These include fresh fruits, fresh vegetables, fresh edible plants, fresh edible seaweeds, fresh or dried meat, fresh fish, raw hams, naturally dried fruits, raw unheated raw milk cheeses, dried fruits, seeds, sprouts ...
- Live foods also contain the digestive enzymes that allow them to be broken down into nutrients during digestion, and this is important as we will see later.
- Enzymes are absolutely essential proteins for cellular biochemical activity. There are two categories:
- Digestive enzymes are essential for the transformation of food into nutrients. When we do not have sufficient digestive enzymes, the food is not destructured satisfactorily, and nutrient extraction is poor. However, the older we age and the less our organism secretes digestive enzymes, the importance of food intake of digestive enzymes is increasing with age. Deficiencies in digestive enzymes contribute to the onset of many chronic diseases. The solution to prevent digestive enzyme deficiencies is to focus on live foods.
- the intestine contains 80% of the body's immune cells. So we can easily imagine the impact of intestinal malfunction on our overall health.
- the mission of the intestines is to carry the food bolus by analyzing and sorting the food, to let the nutrients that the body needs to get into the blood, and to get rid of pathogenic bacteria and non-assimilable foods, which will be eliminated. by the colon.
- microbiota is the name given to the bacterial, fungal and viral population, which colonizes our skin, our mucous membranes, our respiratory tract, our intestines, the vagina in women, and which was transmitted to us by our mother. Its weight oscillates between one and two kilos in the adult.
- the microbiota is an organ of the human body in its own right, just like the heart, brain or spinal cord. It is a complex ecosystem that involves more than a thousand species of bacteria in the same person, and has ten times more bacteria than cells in our body. These bacteria, 99% of which are concentrated in the intestines, form a biofilm, which is a protective film on the surface of our skin, our mucous membranes, our lungs, and our intestines. This biofilm is a barrier against enemies from outside. Among them, viruses, bacteria, toxins and fungi.
- the bacteria constituting this biofilm degrade the dietary fiber - operation impossible without their help -; they synthesize micronutrients such as vitamin K, vitamin B12, folic acid (B9), biotin (B8), riboflavin (B2) and pantothenic acid (B5); they produce fatty acids - which intervene in the control of satiety - and enzymes.
- these bacteria actively participate in maintaining our physical and mental health.
- the intestinal flora also has a strong influence on the functioning of the brain and the nervous system.
- the brain and bacteria of the intestinal flora interact live.
- the present invention promotes the constitution or reconstitution of a quality balanced intestinal microbiota, compatible with the maintenance of health and the prevention of diseases. As we have just seen, health is the result of optimal cellular biochemical activity, only possible if the micronutrient food intake is sufficient.
- cardiovascular diseases such as hypertension, heart failure and stroke;
- Parkinson's and multiple sclerosis Parkinson's and multiple sclerosis.
- treatment occurs once the disease is declared, that is to say when health has failed, and this treatment usually consists in administering a molecule having a specific action on this disease.
- the present invention does not use drugs, it simply promotes the expression of cellular expertise in health. As such, its main role is to prevent diseases, that is to say to prevent their appearance, but it also uses the cellular know-how to restore health, within the meaning of the present invention, or to allow optimal use of the remaining capabilities of a function.
- Health is not a state, but a process. When the latter is functioning normally, our ability to use all our functions is optimal, we feel good, and we do not get sick. When this process fails, our ability to use all of our functions requires more effort, our biological structure is weakened, and the disease is imposed in one way or another. Health, which is a cellular process, is the most effective prevention against all known diseases.
- the food supplement object of the present invention is an imperative in the fight against all current pandemics: cardiovascular diseases, diabetes, osteoporosis, depression, Alzheimer's, Parkinson's, multiple sclerosis, osteoarthritis ...
- the present invention intervenes upstream of diseases, before they appear, when things are still simple, and it suffices to provide our billions of cells with the micronutrients necessary for their work as health experts. An invisible and intangible work of complexity and precision that goes beyond, as we have already said, all current human technological skills.
- a very common treatment for frozen vegetables, bleaching involves heating the plants at a temperature between 85 and 100 ° C for a few minutes, and cooling them immediately. Consequence: the structure of enzymes is damaged, and their activity is permanently stopped. The products being generally immersed in baths, the water-soluble elements such as vitamins and minerals, in particular magnesium, are eliminated from the product.
- Appetizing reserved for all canned fruits, vegetables, meat, fish, or mixed preserves, uses sterilization techniques, whose temperatures are between 115 ° C and 121 ° C.
- Pasteurization involves heating a product between 71 ° C and 85 ° C for 15 to 30 seconds. It concerns cheeses, beer, cider, fruit juices, soups, honey, jams, compote, fruits in syrup, tomato paste, meats ...
- Ultra High Temperature (UHT) processing which involves milk and soups, consists of instantaneously heating the liquid at a temperature of 140 ° C to 150 ° C for 1 to 5 seconds and cooling it immediately.
- Food ionization or cold pasteurization, involves subjecting foods to radioactive radiation - in other words, irradiating them.
- magnesium is not produced by the body.
- the origin of magnesium deficiency is therefore only food and directly related to the massive industrialization of our food.
- magnesium Essential for our immune defenses, our cardiovascular, digestive, neuromuscular, endocrine, osteoarticular, respiratory and ocular activity, magnesium is also important for all major metabolisms: carbohydrate, protein, lipid, phosphocalcic. Without magnesium, our cells can not function properly. This micronutriment conditions not less than three hundred and thirty enzymatic reactions essential to the maintenance of life and our health. Magnesium is involved in the processes of feeding our cells energy, in their division, in cellular respiration, in the repair of DNA, in the exchange and decoding of information, in the synthesis of proteins, in the disposal of waste. Magnesium is also very valuable for its anti-stress, anti-allergic, antianaphylactic, antioxidant, anti-inflammatory effects.
- Magnesium is therefore an absolutely necessary substance, the total absence of which is incompatible with life, and whose deficiency is the source of pathologies. Magnesium is essential to us. Here are some explanations that will convince you ...
- ATP adenosine triphosphate
- DNA polymerase is an enzymatic complex specialized in the duplication and repair of DNA.
- Muscle function is essential. Talk, work, breathe ... It's what allows us to interact with our environment. However, this function is very dependent on magnesium. Contraction and relaxation of the muscles are conditioned by the entry and exit of calcium into the cells. Like a porter, it is magnesium that regulates calcium inputs and outputs.
- magnesium One of the roles of magnesium is to allow the body to repair damaged genes through the action of DNA polymerase. In case of magnesium deficiency, DNA polymerase can not repair damaged genes, and genetically altered cells become potentially cancerous.
- magnesium is also a valuable ally in the prevention of cardiovascular disease. Thus, because it promotes the solubility of calcium in the blood and eliminates calcium deposits, magnesium should be preferred for prevent cardiovascular disease.
- the inventor discovered that, thanks to magnesium, calcium is less soluble and therefore better fixed in the bone structure, which thus retains its strength.
- Magnesium allows all cells in the body, including nerve cells, to go into rest mode. Conversely, magnesium deficiency prevents the expression of the idle mode: it places the cells in an electrical state close to the threshold of excitability. They are then ready to respond to any stimulus. Stress, irritability, anxiety, nervousness, tingling in the feet and hands, sensitivity to noise, light ... are characteristic of magnesium deficiency.
- the inventor has discovered that magnesium is involved in the regulation of nerve activity in humans.
- magnesium salts magnesium ions, magnesium element, Mg ++ , etc.
- Magnesium ion is the only form of magnesium that cells in all living organisms use.
- the magnesium ion is a magnesium atom that has lost two electrons. It is also called Mg ++ , Mg 2+ or magnesium-element.
- magnesium salt is a combination of two elements, the amount of magnesium ions in this salt will depend on its percentage.
- the magnesium chloride hexahydrate (MgCl 2 , 6H 2 O) contains, by mass, 12% magnesium ions. 1 g therefore contains 0.12 g of magnesium ions, ie 120 mg. Magnesium carbonate contains 40% magnesium ions. 1 g therefore contains 0.400 g of magnesium ions, ie 400 mg. However, it is not because a salt contains a lot of magnesium ions that its bioavailability is good. It is the ion associated with magnesium that determines the bioavailability of the whole and its effects on the body. Magnesium oxide is a good example. Despite its high magnesium ion content (60.3%), its bioavailability is poor.
- magnesium chloride and magnesium glycerophosphate two magnesium salts that contain substantially the same proportions of magnesium ions.
- magnesium chloride The bioavailability of magnesium chloride is considered good. Oral intake of magnesium chloride in sufficient quantities to stop a viral or microbial attack, at its first signs, in less than twenty minutes or significantly reduce its consequences. This, thanks to its immediate action on the cellular biochemical activity and consequently on the performances of the immune system.
- magnesium glycerophosphate the absorption of the same amounts of magnesium glycerophosphate does not stop a viral or microbial attack in less than twenty minutes. However, their percentage of magnesium ions is almost identical: 12.4% and 12%. In conclusion, the bioavailability of magnesium chloride should be described as very good, and that of magnesium glycerophosphate less.
- the inventor recommends supplementing the daily diet with a salt rich in micronutrients, including magnesium.
- the inventor has therefore formulated a care product in the form of a dietary supplement. It guarantees the absence of arsenic, lead, mercury, and aluminum. In addition, it prohibits the addition of any cutting product.
- This dietary supplement consists of 99% magnesium chloride, preferably hexahydrate, and fifteen other micronutrients. It comes from a magnesium chloride mine. Each one gram dose contains about 120 magnesium ions and each 2.5 g dose contains about 300 mg magnesium ions.
- Magnesium chloride has, as assets, an immediate effect, a very broad spectrum of action and the lowest toxicity of all salts. On the other hand, in the context of oral consumption, no case of fatal accident has been reported.
- the peculiarity of the food supplement object of the present invention is that it can be consumed every day and all life, and it is not necessary to make cures (to allow the body to eliminate the toxic products contained in most products on the market today).
- the inventor has conducted tests for four years on the consumption of a diet containing more than 50% of live food, accompanied by daily intake of 7.5 g of food supplement object of the present invention, an average consumption of 1,400 mg of magnesium a day. In all cases, it was found an increase in morale and available energy, an improvement in the quality of sleep and recovery, a total dissolution of kidney stones for the people concerned by this problem, an overall improvement of the state of the body, and a noticeable improvement in resistance to viruses and bacteria.
- the food supplement object of the present invention does not act on viruses or bacteria.
- the food supplement object of the present invention is a combination of micronutrients essential to the optimal biochemical activity of our cells, allowing the expression of their daunting capacity for recognition and destruction of viral and bacterial strains, to promote resistance to attack by of all kinds, and to ensure effective prevention against pandemics of cancer, cardiovascular disease, diabetes, osteoporosis, depression, burnout, Parkinson's, Alzheimer's, and multiple sclerosis. osteoarthritis.
- PH Hydrophilicity
- H + When a H 2 O water molecule gains a hydrogen ion H + it becomes an Oxonium H 3 0+ ion. For simplicity, we will call it H +. When a water molecule H 2 O loses a hydrogen ion H + it becomes a hydroxide ion HO-. For simplicity, we'll call it H-.
- water In our body, water has multiple functions. It serves, among other things, solvent, cofactor, and ensures the transport of nutrients. Water participates in the billions of biochemical reactions taking place daily in our body. Finally, the water ensures the evacuation of the waste associated with all these reactions, in the form of urine.
- the H + ions being essentially products of the cellular biochemical activity, their concentration in the urine makes it possible to establish a balance of this biochemical activity.
- the urinary pH can therefore be considered as a marker of the overall quality of the cellular biochemical activity of a human organism.
- Urine pH control is therefore an essential tool for monitoring daily health.
- the food supplement that is the subject of the present invention makes it possible to improve the pH.
- magnesium chloride on cellular biochemical activity is rapid, of the order of fifteen minutes, and measurable thanks to the drop in urinary pH, or the decrease or disappearance of symptoms associated with a viral attack or bacterial.
- magnesium chloride has the best efficacy / safety ratio. Its field of action is very wide. Microbiota, nervous system, immune system ... It restores equilibrium and in particular acid-base balance. It dissolves kidney stones, regulates prostate disorders ... and protects the cells.
- Immune stimulant of the first order, offering a global action on health, magnesium chloride has major assets. Thanks to its effectiveness on the immune system and the cellular biochemical activity, magnesium chloride acts on many pathologies. In the head, many respiratory diseases: tonsillitis, tonsillitis, bronchitis, flu, otitis, sinusitis, pharyngitis. Similarly, childhood diseases such as whooping cough, mumps, measles, rubella, scarlet fever, chickenpox. Also include: chikungunya, gastroenteritis or puerperal fever. Magnesium chloride is also active on herpes, hypertension, chronic mastitis, polio, hay fever, allergies, tetanus, depression, stones or prostate disorders. Its action is also beneficial on everyday pathologies such as constipation, body aches, cramps, contractures, digestive disorders or sleep ...
- Magnesium chloride enhances our immunity. It allows, less than thirty minutes after its administration in vivo - and not in test tubes - to increase up to 330% the phagocytosis of white blood cells. These figures are considerable in immunological matters.
- magnesium chloride is able to stop or stop the flu, whooping cough, poliomyelitis, tetanus, chikungunya, bronchitis ...
- no antiviral offers such protection against the flu, not even Tamiflu or Relenza (registered trademarks).
- Magnesium chloride does not, in itself, have any effect on the flu or any other infection. It simply gives our cells, and in a highly assimilable form, the magnesium ions they absolutely need to ensure optimal cell biochemical activity, the most advanced and effective "cell technology" available for identification and destruction. viral and microbial strains by the immune system.
- magnesium chloride is therefore clearly established, for prevention as for the treatment of a number of pathologies, but also in the fight against the global development of antibiotic resistance.
- halogenated magnesium salts many of those who have recurrent illnesses - colds, tonsillitis, enteritis, hepatic congestion, cholecystitis, cystitis, herpes, mycosis ... - see them becoming less frequent or disappearing. Those who are regularly affected by seasonal affections - flu, common cold, allergy - are no longer sensitive, or much less.
- Magnesium chloride has exceptional properties on the biochemical activity of our cells, and therefore on our immune system. So that its some inconveniences (slight bitterness, laxative effect the first times) will be quickly forgiven and forgotten. Protecting in a simple gesture, the whole of his body and enjoy a maximum life expectancy in good health is in itself a real motivation that allows to pass this course with ease.
- Haemophilia is currently the only justified contraindication to the use of magnesium chloride, whose action fluidifies the blood. This peculiarity, which gives it certain health properties, constitutes, until proven otherwise, an obstacle to its use.
- the consumption of the food supplement object of the present invention is preferably integrated into a food environment containing at least 30% of live food, foods rich in micronutrients and digestive enzymes, which save our biological resources.
- the choice of organic foods is recommended where possible because their micronutrient value is statistically higher than that of foods from industrial agriculture.
- the ban of pesticides and ionized products in this sector also allows a considerable saving of our biological resources.
- the method here is to take a dose of 2.5 g. in 10 cl of water.
- the volume of water is important: it is better to respect it. But do not worry if it does not match the centilitre, the efficiency remains unchanged.
- a simple method in case of attack the method "3 times 1/3/6", that is to say three times an hour apart, three times to three hours apart, three times to six hours apart.
- Phase 1 a dose of 2.5 g of dietary supplement object of the present invention in 10 cl of water every hour, 3 times.
- Phase 2 a dose of 2.5 g of dietary supplement object of the present invention in 10 cl of water every 3 hours, 3 times.
- Phase 3 a dose of 2.5 g of dietary supplement object of the present invention in 10 cl of water every 6 hours, 3 times.
- the inventor recommends, to prevent the effects of influenza:
- our intestinal system must be able to extract these micronutrients from food, and the magnesium contained in the food supplement that is the subject of the present invention improves the functioning of our microbiota, which improves the functioning of our intestines, which improves the intestinal extraction of the micronutrients contained in live foods.
- the food supplement object of the present invention restores the acid-base balance of the digestive system, and allows the microbiota to be a balanced ecosystem. By promoting fermentation processes, it protects our body. In addition, simultaneously, the food supplement object of the present invention limits the process of putrefaction, process causing many pathologies and intestinal disorders ...
- the daily intake of food supplement object of the present invention allows the nerve cells to go to sleep.
- the result is generally very effective. People quickly find a quality sleep, particularly restorative.
- Table 1 shows results obtained for a population of patients with diabetes. It is found that, in three months of daily consumption of the food supplement object of the present invention, the blood glucose is, on average, reduced by more than half.
- Table 2 shows results obtained on a population of patients with high blood pressure.
- the time interval between two arterial blood pressure readings is three weeks. It is found that, in nine weeks of daily consumption of the food supplement object of the present invention, the tensions are, on average, reduced by more than 20%.
- kidney stones For kidney stones, a 61-year-old patient was treated. Freshly operated on the right kidney for kidney stones and waiting for its operation of the left kidney, the patient consumed 2.5 grams of the food supplement object of the present invention for seven days. Taken with a violent fever, he decides to see his surgeon urgently. The latter, after examination, announces that the operation of the left kidney is no longer necessary, the calculations he proposed to operate having descended.
- hemorrhoids a patient suffering from frequent and particularly painful hemorrhoids has seen the problem disappear within the first week of treatment (two daily doses of 2.5 grams).
- GASTROOESOPHAGIAN fish 2.5 g / day helps to eliminate bad breath at the end
- HALEINE a few days.
- NCB initials, age 28 years, gender F.
- Pathology 26-week-pregnant woman with amenorrhea and threatened abortion (pregnancy at risk).
- Menorrhea are normalized, glycemic 1 .03 at last control. Awaiting the results of the latest biological, biochemical and ultrasound examinations.
- a gel is obtained when the amount, by mass, of magnesium glycerophosphate is greater than the amount, by mass, of magnesium chloride.
- This gel has interesting properties when the amount, by mass, of magnesium glycerophosphate is greater than five times the amount, by mass, of magnesium chloride.
- the proportion by weight of magnesium chloride, magnesium glycerophosphate and water is greater than 95%.
- 2.5 grams of magnesium chloride hexahydrate and 2.5 grams of magnesium glycerophosphate are mixed in 35 grams of water.
- the compound thus obtained may be named magnesium glycero-chlorophosphate.
- this product preferably comprises a flavoring agent, or flavoring agent.
- the flavoring agent gives a sweet flavor to the food supplement.
- the food supplement can look like jam or yoghurt.
- a solid which can serve as a candy.
- the gel can also be integrated into a shampoo, a soap, a skin cream or a toothpaste.
Abstract
Description
Claims
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR1401736 | 2014-07-28 | ||
FR1401736A FR3024019B1 (en) | 2014-07-28 | 2014-07-28 | FOOD SUPPLEMENT FOR IMPROVING THE FUNCTIONING OF LIVING CELLS AND ASSOCIATED METHOD |
FR1554530 | 2015-05-20 | ||
FR1554530A FR3024031B1 (en) | 2014-07-28 | 2015-05-20 | CARE AND SHAMPOO PRODUCT, SOAP, CREAM, TOOTHPASTE, FOOD SUPPLEMENT AND BONBON COMPRISING SAME |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2016016264A1 true WO2016016264A1 (en) | 2016-02-04 |
Family
ID=52692665
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2015/067308 WO2016016264A1 (en) | 2014-07-28 | 2015-07-28 | Healthcare product made from magnesium for improving the functioning of living cells and associated device |
Country Status (2)
Country | Link |
---|---|
FR (2) | FR3024019B1 (en) |
WO (1) | WO2016016264A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR3071727A1 (en) * | 2017-09-11 | 2019-04-05 | Yvan ERBS | A CARE PRODUCT FOR REDUCING THE RISK OF OCCURRENCE OF AT LEAST ONE HEALTH DISORDER OR DISORDER |
EP3791884A1 (en) * | 2019-09-16 | 2021-03-17 | Oskar Bunz | Combination of heparin and magnesium salt for the treatment of viral infections |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5475929A (en) * | 1994-11-14 | 1995-12-19 | Yancey; Ira T. | Device and method for estimating percentage of calories from fat |
US5545670A (en) * | 1991-09-13 | 1996-08-13 | Bissbort; Siegbert H. | Composition and method for the treatment of chronic fatigue syndrome |
US20050214388A1 (en) * | 2004-02-18 | 2005-09-29 | Gorham Thomas R | Multivitamin formulations containing controlled-release magnesium |
US20080193525A1 (en) * | 2007-02-09 | 2008-08-14 | Board Of Regents, The University Of Texas System | Potassium-magnesium citrate as a surrogate of the dash diet in managing hypertension |
US20100236975A1 (en) * | 2006-03-27 | 2010-09-23 | Hill's Pet Nutrition, Inc. | Methods for predicting oxalate and struvite stone formation in animals |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ZA73467B (en) * | 1972-02-25 | 1973-10-31 | Hoffmann La Roche | Mineral salts containing preparation |
FR2647347A1 (en) * | 1989-05-24 | 1990-11-30 | Lucien Laboratoires | MG2 + ION AGENTS AND COMPLEXES FACILITATING ABSORPTION OF MAGNESIUM IN HUMAN OR ANIMAL ORGANISMS, AND PHARMACEUTICAL OR DIETETIC COMPOSITIONS USEFUL FOR MAGNESIUM ADMINISTRATION IN HUMAN OR ANIMAL ORGANISM |
RU2293551C1 (en) * | 2005-05-23 | 2007-02-20 | Ооо "Вдс" | Composition for mouth cavity disease prophylaxis |
WO2009086073A1 (en) * | 2007-12-21 | 2009-07-09 | Alcon Research, Ltd. | Stabilized glycerophosphate-containing surgical irrigating solution |
EA011254B1 (en) * | 2008-02-07 | 2009-02-27 | Общество С Ограниченной Ответственностью "Вдс" | Gel for remineralization of tooth tissues |
EA200801824A1 (en) * | 2008-07-07 | 2009-08-28 | Общество С Ограниченной Ответственностью "Вдс" | MEDICAL-PREVENTIVE COMPOSITION FOR CARE OF ORAL CAVITY |
-
2014
- 2014-07-28 FR FR1401736A patent/FR3024019B1/en active Active
-
2015
- 2015-05-20 FR FR1554530A patent/FR3024031B1/en active Active
- 2015-07-28 WO PCT/EP2015/067308 patent/WO2016016264A1/en active Application Filing
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5545670A (en) * | 1991-09-13 | 1996-08-13 | Bissbort; Siegbert H. | Composition and method for the treatment of chronic fatigue syndrome |
US5475929A (en) * | 1994-11-14 | 1995-12-19 | Yancey; Ira T. | Device and method for estimating percentage of calories from fat |
US20050214388A1 (en) * | 2004-02-18 | 2005-09-29 | Gorham Thomas R | Multivitamin formulations containing controlled-release magnesium |
US20100236975A1 (en) * | 2006-03-27 | 2010-09-23 | Hill's Pet Nutrition, Inc. | Methods for predicting oxalate and struvite stone formation in animals |
US20080193525A1 (en) * | 2007-02-09 | 2008-08-14 | Board Of Regents, The University Of Texas System | Potassium-magnesium citrate as a surrogate of the dash diet in managing hypertension |
Non-Patent Citations (3)
Title |
---|
GUERRERO-ROMERO ET AL: "Oral Magnesium supplementation improves insulin sensitivity in non-diabetic subjects with insulin resistance. A double-blind placebo-controlled randomized trial", DIABETES & METABOLISM, PARIS, AMSTERDAM, NL, vol. 30, no. 3, 1 June 2004 (2004-06-01), pages 253 - 258, XP005942988, ISSN: 1262-3636, DOI: 10.1016/S1262-3636(07)70116-7 * |
PURVIS J R ET AL: "EFFECT OF ORAL MAGNESIUM SUPPLEMENTATION ON SELECTED CARDIOVASCULAR RISK FACTORS IN NON-INSULIN-DEPENDENT DIABETICS", ARCHIVES OF FAMILY MEDICINE, AMERICAN MEDICAL ASSOCIATION, CHICAGO, IL, US, vol. 3, no. 6, 1 June 1994 (1994-06-01), pages 503 - 508, XP009023293, ISSN: 1063-3987, DOI: 10.1001/ARCHFAMI.3.6.503 * |
YAMORI YUKIO ET AL: "Low cardiovascular risks in the middle aged males and females excreting greater 24-hour urinary taurine and magnesium in 41 WHO-CARDIAC study populations in the world", JOURNAL OF BIOMEDICAL SCIENCE, KLUWER ACADEMIC PUBLISHERS, DO, vol. 17, no. Suppl 1, 24 August 2010 (2010-08-24), pages S21, XP021071281, ISSN: 1423-0127, DOI: 10.1186/1423-0127-17-S1-S21 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR3071727A1 (en) * | 2017-09-11 | 2019-04-05 | Yvan ERBS | A CARE PRODUCT FOR REDUCING THE RISK OF OCCURRENCE OF AT LEAST ONE HEALTH DISORDER OR DISORDER |
EP3791884A1 (en) * | 2019-09-16 | 2021-03-17 | Oskar Bunz | Combination of heparin and magnesium salt for the treatment of viral infections |
Also Published As
Publication number | Publication date |
---|---|
FR3024031A1 (en) | 2016-01-29 |
FR3024031B1 (en) | 2018-11-02 |
FR3024019A1 (en) | 2016-01-29 |
FR3024019B1 (en) | 2017-11-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Campbell-McBride | Gut and psychology syndrome: Natural treatment for autism, dyspraxia, ADD, dyslexia, ADHD, depression, schizophrenia | |
Edenfield | Sports supplements: Pearls and pitfalls | |
Tirla et al. | New insight and future perspectives on nutraceuticals for improving sports performance of combat players: Focus on natural supplements, importance and advantages over synthetic ones | |
Morley | Nutrition and the aging male | |
WO2016016264A1 (en) | Healthcare product made from magnesium for improving the functioning of living cells and associated device | |
Rubin | Patient Heal Thyself | |
US6932987B1 (en) | Chemical composition and method for enhancing metabolism | |
Stengler | The Natural Physician's Healing Therapies: Proven Remedies Medical Doctors Don't Know | |
FR3070856A1 (en) | A CARE PRODUCT FOR REDUCING THE RISK OF OCCURRENCE OF AT LEAST ONE HEALTH DISORDER OR DISORDER | |
Sircus | Sodium Bicarbonate: Nature's Unique First Aid Remedy | |
Trivieri Jr | Coconuts for Your Health: Nature’s Most Delicious & Effective Remedy | |
Mindell | Earl Mindell's Supplement Bible: A Comprehensive Guide to Hundreds of NEW Natural Products that Will Help You Live Longer, Look Better, Stay Heathier, Improve Strength and Vitality, and Much More! | |
Tait | Your Health, Your Vitality, Your Choice: An Interlude with an Esoteric Herbalist | |
Cook | Pain Erasers: The Complete Natural Medicine Guide to Safe, Drug-Free Relief | |
Miller | The Anti-Anxiety Diet: A Whole Body Program to Stop Racing Thoughts, Banish Worry and Live Panic-Free | |
Brandon | The Everything Guide to Aloe Vera for Health: Discover the Natural Healing Power of Aloe Vera | |
Greber | Chronic Digestive Disorders | |
Bakhtyarovna et al. | THE MOST IMPORTANT ROLE OF VITAMIN C IN THE HUMAN BODY | |
Elstein | Eternal Health | |
Willix | The Rejuvenation Solution: Age in Reverse--7 Proven Medical Breakthroughs That Prevent Disease and Make You Feel Years Younger | |
Rife | DEMENTIA WARS | |
Klatz et al. | Anti-Aging Therapeutics | |
Maccaro | Natural Health Remedies: Your AZ Blueprint for Vibrant Health | |
Meyer | SPIRULINA Survival Food for a New Era: Amazing Healing Success with the Blue-green Algae-Delicious Recipes with the Primal Nourishment | |
Null | Bottom Line's Power Aging: The Revolutionary Program to Control the Symptons of Aging Naturally |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15767419 Country of ref document: EP Kind code of ref document: A1 |
|
WPC | Withdrawal of priority claims after completion of the technical preparations for international publication |
Ref document number: 1554530 Country of ref document: FR Date of ref document: 20170103 Free format text: WITHDRAWN AFTER TECHNICAL PREPARATION FINISHED Ref document number: 1401736 Country of ref document: FR Date of ref document: 20161230 Free format text: WITHDRAWN AFTER TECHNICAL PREPARATION FINISHED |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: CONSTATATION DE LA PERTE D'UN DROIT CONFORMEMENT A LA REGLE 112(1) CBE (OEB FORM 1205A EN DATE DU 23.04.2018) |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 15767419 Country of ref document: EP Kind code of ref document: A1 |